Fig. 1From: Non-inferiority versus superiority drug claims: the (not so) subtle distinctionComparison of interpretation of outcomes between the FDA NI guidance document and what is proposed. FDA interpretation is provided for scenarios C and E (Figure 2 in [2]). See also Figure 6 in [4] which discusses the same example. Cel celecoxib, Nap naproxen, NI non-inferiority, sup superiorBack to article page